These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 27861184

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A, Marai I, Suleiman M, Blich M, Lorber A, Gepstein L, Boulos M.
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
    Wangüemert Pérez F, Hernández Afonso JS, Groba Marco MDV, Caballero Dorta E, Álvarez Acosta L, Campuzano Larrea O, Pérez G, Brugada Terradellas J, Brugada Terradellas R.
    Rev Esp Cardiol (Engl Ed); 2018 Mar; 71(3):185-191. PubMed ID: 28789916
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H, van der Werf C, Roses-Noguer F, Adler A, Sumitomo N, Veltmann C, Rosso R, Bhuiyan ZA, Bikker H, Kannankeril PJ, Horie M, Minamino T, Viskin S, Knollmann BC, Till J, Wilde AA.
    Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
    [Abstract] [Full Text] [Related]

  • 10. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
    Watanabe H, Knollmann BC.
    J Electrocardiol; 2011 Apr; 44(6):650-5. PubMed ID: 21872879
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia.
    Hong RA, Rivera KK, Jittirat A, Choi JJ.
    Pacing Clin Electrophysiol; 2012 Jul; 35(7):794-7. PubMed ID: 22553997
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia.
    Imberti JF, Underwood K, Mazzanti A, Priori SG.
    Heart Lung Circ; 2016 Aug; 25(8):777-83. PubMed ID: 26948768
    [Abstract] [Full Text] [Related]

  • 17. Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome.
    Schneider HE, Steinmetz M, Krause U, Kriebel T, Ruschewski W, Paul T.
    Clin Res Cardiol; 2013 Jan; 102(1):33-42. PubMed ID: 22821214
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. BASIC AND CLINICAL INSIGHTS IN CATECHOLAMINERGIC (FAMILIAL) POLYMORPHIC VENTRICULAR TACHYCARDIA.
    Márquez MF, Totomoch-Serra A, Rueda A, Avelino-Cruz JE, Gallegos-Cortez A.
    Rev Invest Clin; 2019 Jan; 71(4):226-236. PubMed ID: 31448784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.